Gemifloxacin: a new fluoroquinolone

Area of Science:

• Pharmacology and Microbiology
• Antimicrobial drug discovery and development

Background:

• Community-acquired respiratory tract infections (CARTIs) are significant health concerns.
• Emergence of multi-drug resistant pathogens, particularly Streptococcus pneumoniae, poses treatment challenges.
• Fluoroquinolones are a critical class of antibiotics for treating bacterial infections.

Purpose of the Study:

• To evaluate the in vitro activity of gemifloxacin against common respiratory pathogens.
• To assess the pharmacokinetic profile and clinical efficacy of gemifloxacin.
• To investigate gemifloxacin's dual-targeting mechanism against DNA gyrase and topoisomerase IV.

Main Methods:

• Determination of minimal inhibitory concentrations (MIC 90) against various Gram-positive, Gram-negative, and atypical pathogens.
• Pharmacokinetic studies to assess once-daily oral administration.
• Clinical efficacy trials in patients with community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).

Main Results:

• Gemifloxacin demonstrated potent in vitro activity with low MIC 90 values against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, and Legionella spp.
• The drug is effective against beta-lactamase producing strains and penicillin/macrolide resistant S. pneumoniae.
• Clinical studies showed efficacy in CAP and AECB, with favorable comparisons to clarithromycin regarding exacerbation-free periods and H. influenzae eradication.

Conclusions:

• Gemifloxacin exhibits broad-spectrum in vitro activity and is effective in treating community-acquired lower respiratory tract infections.
• Its dual-targeting mechanism is crucial for combating quinolone resistance.
• Gemifloxacin offers a valuable therapeutic option with a comparable adverse effect profile to existing treatments.